Gsa Capital Partners LLP Akebia Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $145,970 - $223,821	486,568 New	486,568 $154,000
Q2 2022 Aug 09, 2022	SELL	$0.32 - $0.67 $17,398 - $36,427	-54,370 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.72 - $2.93 $39,146 - $159,304	54,370 New	54,370 $39,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $574,889 - $849,615	-254,376 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $597,783 - $986,978	254,376 New	254,376 $733,000
Q1 2021 May 10, 2021	SELL	$2.92 - $5.06 $375,587 - $650,847	-128,626 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$2.22 - $3.78 $86,497 - $147,280	38,963 Added 43.45%	128,626 $360,000
Q3 2020 Nov 06, 2020	BUY	$2.39 - $13.08 $214,294 - $1.17 Million	89,663 New	89,663 $225,000
Q4 2019 Feb 12, 2020	SELL	$3.16 - $6.73 $82,750 - $176,238	-26,187 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $92,963 - $141,409	26,187 New	26,187 $103,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $395M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.